WHO Approves New Malaria Treatment for Babies, Bringing Eradication Closer

The World Health Organization has approved the first malaria treatment specifically for newborns and young infants, marking a significant milestone in global efforts to combat the disease.

The approval covers a new formulation of artesunate-amodiaquine, which has been shown to be safe and effective in babies under five kilograms. This development addresses a critical gap in malaria treatment, as previous options were either unsuitable or not tested in this youngest age group.

Health officials say the decision could save thousands of lives each year in sub-Saharan Africa, where malaria remains a leading cause of death among infants. The treatment is expected to be rolled out through national health programs with support from international partners.

Experts noted that while the approval is a major step forward, challenges remain in ensuring access to the drug in remote and underserved areas. Continued investment in healthcare infrastructure and training will be essential to maximize its impact.

The WHO’s endorsement follows rigorous clinical trials and regulatory review, confirming that the benefits of the treatment outweigh any risks for vulnerable newborns. This achievement reflects years of collaboration between researchers, pharmaceutical companies, and public health agencies.

As malaria continues to pose a serious threat to young children worldwide, this approval represents progress toward the goal of reducing infant mortality and eventually eliminating the disease.